Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Research & Development (2020 - 2025)

NeuroPace has reported Research & Development over the past 6 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Research & Development at $7.0 million for Q4 2025, up 16.15% from a year ago — trailing twelve months through Dec 2025 was $27.9 million (up 17.9% YoY), and the annual figure for FY2025 was $27.9 million, up 17.9%.
  • Research & Development for Q4 2025 was $7.0 million at NeuroPace, up from $6.6 million in the prior quarter.
  • Over the last five years, Research & Development for NPCE hit a ceiling of $7.4 million in Q1 2025 and a floor of $4.1 million in Q1 2021.
  • Median Research & Development over the past 5 years was $5.6 million (2022), compared with a mean of $5.6 million.
  • Peak annual rise in Research & Development hit 36.44% in 2021, while the deepest fall reached 15.17% in 2021.
  • NeuroPace's Research & Development stood at $5.3 million in 2021, then decreased by 4.79% to $5.1 million in 2022, then increased by 5.66% to $5.4 million in 2023, then rose by 12.52% to $6.0 million in 2024, then increased by 16.15% to $7.0 million in 2025.
  • The last three reported values for Research & Development were $7.0 million (Q4 2025), $6.6 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.